Clinical Trials Browser

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03894215 2026-03-27

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Phase 2 Terminated

211 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 1 Recruiting

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT06336902 2026-03-17

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Phase 1 Recruiting

15 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

197 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06279130 2026-03-05

NEOASIS

Phase 2/3 Recruiting

133 enrolled

Other solid neoplasm

Resectable MMR-deficient Solid Tumors

NCT07193862 2026-02-27

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Phase EARLY_PHASE1 Recruiting

10 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT05928806 2026-02-11

ARCITECT

Phase 2 Suspended

120 enrolled

Genitourinary

Advanced Renal Cell Carcinoma

NCT07227636 2026-02-06

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Phase 2 Recruiting

284 enrolled

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

Phase 2 Active not recruiting

16 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05672316 2026-01-28

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Phase 1/2 Active not recruiting

28 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04028063 2026-01-27

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Phase 2 Recruiting

65 enrolled

Sarcoma

NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 2 Recruiting

70 enrolled

Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06076837 2026-01-12

The Seven Trial: Exploiting the Unfolded Protein Response

Phase 1 Active not recruiting

6 enrolled

Gastrointestinal

Pancreatic Cancer Metastatic

NCT06411691 2025-12-18

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Phase 1 Recruiting

54 enrolled

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Phase 1/2 Recruiting

38 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Recruiting

37 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT06843434 2025-12-02

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Microsatellite Stable Rectal Carcinoma

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

20 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 1/2 Active not recruiting

107 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT05864534 2025-10-03

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

25 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05608044 2025-09-04

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2 Active not recruiting

234 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06843551 2025-08-14

EMPIRE

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03104699 2025-07-30

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Phase 1/2 Completed

211 enrolled 29 charts

Gynecologic

Uterine Cervical Neoplasms

NCT05571293 2025-07-30

NEST-1

Phase 2 Suspended

36 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2 Recruiting

26 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05891821 2025-05-08

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Phase 2 Recruiting

20 enrolled

Lymphoid

Lymphoma

NCT06322108 2025-05-08

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Phase 2 Recruiting

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05377528 2025-04-30

Study of AGEN1571 in Participants With Advanced Solid Tumors

Phase 1 Completed

22 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05572970 2025-04-30

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Available

Tumor-Agnostic

Neoplasms

Clinical Trials

BATTMAN

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

CIME

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

NEOASIS

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

ARCITECT

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

BBOpCo

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

The Seven Trial: Exploiting the Unfolded Protein Response

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

EMPIRE

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

NEST-1

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Study of AGEN1571 in Participants With Advanced Solid Tumors

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)